Sanofi, an R&D driven, AI-powered biopharma company, announces the completion of its acquisition of Vicebio Ltd (Vicebio).

This acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with Vicebio’s ‘Molecular Clamp’ technology.

The acquired vaccine candidate complements Sanofi’s position in respiratory vaccines. It enables Sanofi to offer increased physician and patient choice in RSV and HMPV by adding a non-mRNA vaccine to its pipeline.

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. The company apply its deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more.